Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash ...

Fintel reports that on November 21, 2025, Leerink Partners maintained coverage of Moderna (NasdaqGS:MRNA) with a Underperform ...

Fintel reports that on November 21, 2025, Piper Sandler reiterated coverage of Moderna (NasdaqGS:MRNA) with a Overweight ...

A clinical trial testing an experimental vaccine for the Epstein-Barr virus (EBV) in people with MS is now recruiting ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Jay Bhattacharya's new "plan" is really an admission that if there's a new pandemic, he’s not competent enough to do any of ...

The Dow Jones Industrial Average edged down 0.8% to 45,752.26, while the S&P 500 dropped 1.56% to 6,538.76 and the Nasdaq ...

Health-care companies fell, but not by as much as the broad market, amid deal activity. Exact Sciences rallied after Abbott Laboratories agreed to buy the cancer diagnostics company for about $21 ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...